drugset / Trial / NCT07628582
A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies
Phase 1
Not yet recruiting
48 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label and dose-escalation clinical study to evaluate the LVIVO-TaVec122 product in adult subjects with Relapsed/Refractory B-cell Malignancies.
Timeline
- Start
- 2026-09-15
- Primary completion
- 2028-10-30
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVIVO-TaVec122 | Unknown | — | — |